EGFR Inhibitors
Santa Cruz Biotechnology now offers a broad range of EGFR Inhibitors. The EGF receptor family comprises several related receptor tyrosine kinases that are frequently overexpressed in a variety of carcinomas. Upregulation of EGFR is associated with tumor progression. Abrogation of EGFR may be achieved with the use of EGFR Inhibitors with potential results in cell cycle arrest, apoptosis or dedifferentiation of cancer cells. EGFR Inhibitors offered by Santa Cruz inhibit EGFR and, in some cases, other receptor tyrosine kinases and tumor progression related proteins. View detailed EGFR Inhibitor specifications, including EGFR Inhibitor CAS number, molecular weight, molecular formula and chemical structure, by clicking on the product name.
Items 91 to 98 of 98 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
3-(4-Hydroxybenzylidenyl)indolin-2-one | 293302-14-4 | sc-202412 sc-202412A | 1 mg 5 mg | $55.00 $216.00 | ||
3-(4-Hydroxybenzylidenyl)indolin-2-one exhibits potent EGFR inhibition through its ability to disrupt key protein-protein interactions within the receptor's dimerization interface. The compound's unique indolinone scaffold promotes specific π-π stacking and van der Waals forces, enhancing binding affinity. Its reaction kinetics indicate a slow onset of action, allowing for gradual receptor modulation. Furthermore, its lipophilic characteristics may influence cellular uptake and localization, impacting downstream signaling pathways. | ||||||
WZ 3146 | 1214265-56-1 | sc-364654 sc-364654A | 5 mg 10 mg | $305.00 $480.00 | ||
WZ 3146 is a selective inhibitor of EGFR that operates by stabilizing the inactive conformation of the receptor, effectively preventing its activation. The compound's unique structural features facilitate strong hydrogen bonding and hydrophobic interactions, which are critical for its binding efficacy. Its kinetic profile reveals a rapid association rate, leading to swift receptor occupancy. Additionally, the compound's solubility properties may enhance its distribution within cellular environments, influencing EGFR-mediated signaling cascades. | ||||||
WZ8040 | 1214265-57-2 | sc-364656 sc-364656A | 5 mg 10 mg | $255.00 $480.00 | ||
WZ8040 is a potent EGFR modulator characterized by its ability to disrupt the receptor's dimerization process. This compound exhibits unique electrostatic interactions that favorably alter the receptor's conformational dynamics, leading to a decrease in downstream signaling. Its reaction kinetics demonstrate a slow dissociation rate, ensuring prolonged engagement with the target. Furthermore, WZ8040's lipophilic nature enhances membrane permeability, potentially affecting cellular uptake and localization. | ||||||
O-tert-Butyl-dimethylsilyl Curcumin | 911292-36-9 | sc-396137 | 100 mg | $290.00 | ||
O-tert-Butyl-dimethylsilyl Curcumin exhibits unique interactions with the epidermal growth factor receptor (EGFR) through its ability to modulate conformational dynamics. This compound enhances the stability of the receptor's inactive state, effectively disrupting downstream signaling pathways. Its bulky tert-butyl and dimethylsilyl groups contribute to increased lipophilicity, promoting selective membrane permeability. The compound's reactivity profile allows for efficient participation in various chemical transformations, making it a versatile tool in biochemical research. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
Erlotinib, Free Base, is a selective EGFR inhibitor that uniquely interacts with the ATP-binding site, stabilizing the inactive conformation of the receptor. This compound exhibits a high affinity for the kinase domain, resulting in a significant reduction of phosphorylation events. Its distinct molecular structure allows for enhanced solubility in organic solvents, facilitating diverse experimental applications. Additionally, Erlotinib's ability to form hydrogen bonds contributes to its specificity and binding efficacy. | ||||||
PD 158780 | 171179-06-9 | sc-358789 | 10 mg | $127.00 | 2 | |
PD 158780 is a selective inhibitor of the epidermal growth factor receptor (EGFR) that engages in specific molecular interactions, particularly through hydrogen bonding and hydrophobic contacts. Its unique structure allows it to effectively block the ATP-binding site, altering the receptor's activation state. This compound exhibits distinct reaction kinetics, characterized by rapid binding and prolonged inhibition, which can significantly impact downstream signaling cascades. Its physicochemical properties enhance its affinity for target sites, facilitating targeted interactions within cellular environments. | ||||||
AG 30 | 122520-79-0 | sc-202042 sc-202042A | 5 mg 10 mg | $33.00 $80.00 | 1 | |
Tyrphostin AG 30 is a potent inhibitor of the epidermal growth factor receptor (EGFR), characterized by its ability to disrupt key signaling pathways. It selectively binds to the receptor's active site, employing a combination of van der Waals forces and electrostatic interactions to stabilize its conformation. This compound demonstrates unique reaction kinetics, with a fast association rate and a slow dissociation rate, leading to sustained receptor inhibition. Its structural features contribute to a high degree of specificity, minimizing off-target effects and enhancing its interaction profile within cellular systems. | ||||||
AST-1306 | 897383-62-9 | sc-503138 | 5 mg | $490.00 | ||
AST-1306 is an innovative compound that exhibits unique interactions with the epidermal growth factor receptor (EGFR). Its structural conformation allows for selective binding, influencing downstream signaling pathways. The compound's ability to modulate receptor dimerization and activation is notable, as it alters the phosphorylation state of key residues. Furthermore, its dynamic solubility profile enhances bioavailability, impacting its kinetic behavior in various environments. | ||||||